Cargando…
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
BACKGROUND: Doxycycline is often used for treating COVID-19 respiratory symptoms in the community despite an absence of evidence from clinical trials to support its use. We aimed to assess the efficacy of doxycycline to treat suspected COVID-19 in the community among people at high risk of adverse o...
Autores principales: | Butler, Christopher C, Yu, Ly-Mee, Dorward, Jienchi, Gbinigie, Oghenekome, Hayward, Gail, Saville, Benjamin R, Van Hecke, Oliver, Berry, Nicholas, Detry, Michelle A, Saunders, Christina, Fitzgerald, Mark, Harris, Victoria, Djukanovic, Ratko, Gadola, Stephan, Kirkpatrick, John, de Lusignan, Simon, Ogburn, Emma, Evans, Philip H, Thomas, Nicholas P B, Patel, Mahendra G, Hobbs, F D Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315758/ https://www.ncbi.nlm.nih.gov/pubmed/34329624 http://dx.doi.org/10.1016/S2213-2600(21)00310-6 |
Ejemplares similares
-
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
por: Dorward, Jienchi, et al.
Publicado: (2022) -
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
por: Yu, Ly-Mee, et al.
Publicado: (2021) -
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
por: Hayward, Gail, et al.
Publicado: (2021) -
Inclusion and diversity in the PRINCIPLE trial
por: Patel, Mahendra G, et al.
Publicado: (2021) -
Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: A randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU)
por: Dhar, Raja, et al.
Publicado: (2023)